ICH M9 - reverse engineering? [Regulatives / Guidelines]

posted by MSimoes – Portugal, 2020-09-16 16:01 (647 d 11:29 ago) – Posting: # 21922
Views: 1,063

Dear BEBAC team,

Do you have experience with biowaivers and ICH M9 guideline?
When the M9 guidance mentions that we should have a formulation "qualitatively the same and quantitatively similar", especially for BCS class III drugs, how should be the quantitative formulation of the RLD justified? Is literature data enough, or do we need reverse engineering - and in this case, what is the level required (Q2 or Q3)? Only one method for each attribute or orthogonal analysis required?

This is not easy for some specific formulations, and the M9 is not clear in these requirements.

Thanks in advance for sharing your experience!

Kind regards,
Marta

Regards,
MSimoes

Complete thread:

UA Flag
Activity
 Admin contact
22,167 posts in 4,645 threads, 1,572 registered users;
online 9 (0 registered, 9 guests [including 4 identified bots]).
Forum time: Sunday 03:30 CEST (Europe/Vienna)

The person interested in success has to learn
to view failure as a healthy, inevitable part
of the process of getting to the top.    Joyce Brothers

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5